Portfolio Overview
The Obesity & Metabolic Health Portfolio is a thematic portfolio focused on the rapidly evolving landscape of obesity and metabolic disease treatments. With a global mandate, the portfolio captures opportunities across the value chain, including GLP-1 receptor agonists, oral small molecules, and innovative delivery mechanisms. As of August 5, 2026, the portfolio holds ten positions, with a mix of established pharmaceutical giants and emerging biotech innovators.
Recent Performance Drivers
Over the past week, the portfolio has benefited from strong momentum in several key holdings:
- Zealand Pharma (ZLDPF) – Up 13.01% since inception, driven by positive clinical data for its long-acting GLP-1/GLP-2 dual agonist in obesity and metabolic dysfunction-associated steatohepatitis (MASH).
- Rhythm Pharmaceuticals (RYTM) – Up 26.01%, reflecting robust sales growth for Imcivree and expanding label potential in rare melanocortin-4 receptor pathway deficiencies.
- Structure Therapeutics (GPCR) – Up 17.76%, supported by promising Phase 2 results for its oral GLP-1 agonist, GSBR-1290, which showed competitive efficacy and a favorable safety profile.
Conversely, Viking Therapeutics (VKTX) has declined 20.46% from its initial quote, likely due to profit-taking and competitive concerns following recent data from rival programs. AstraZeneca (AZN) is down 4.80% since its pick on August 5, reflecting broader market volatility and sector rotation.
Risk Concentration and Diversification
The portfolio is well-diversified across market capitalizations and therapeutic approaches. Large-cap holdings such as AstraZeneca and Boehringer Ingelheim (via 3SBio) provide stability, while mid-cap names like Rhythm and Structure offer growth potential. Small-cap and micro-cap positions (Altimmune, Fractyl Health) add high-risk/high-reward exposure. However, there is a notable concentration in GLP-1-related mechanisms, which is inherent to the theme. Investors should be aware of the sector’s sensitivity to clinical trial outcomes and regulatory news.
What to Watch Next
- Clinical Readouts: Upcoming data from Viking’s VK2735 oral program and Structure’s GSBR-1290 Phase 2b results will be critical catalysts.
- Regulatory Decisions: FDA decisions on new indications for existing drugs, such as Rhythm’s Imcivree in additional genetic obesity syndromes, could drive significant moves.
- Competitive Landscape: The entry of oral GLP-1s from major players like Novo Nordisk and Eli Lilly may pressure smaller developers; monitor differentiation and pricing.
- Financing and Cash Runway: For micro-caps like Fractyl and Altimmune, ensure adequate cash to reach next milestones.
Position Management
All current positions are within their minimum holding periods and none exhibit thesis-breaking developments. Therefore, no positions are recommended for closure at this time. We will continue to monitor each holding for signs of fundamental deterioration or valuation overextension.
Risk Disclaimer
This article is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Investing in biotechnology and pharmaceutical companies involves significant risks, including clinical trial failures, regulatory hurdles, and market volatility. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.